The purpose of the invitation to tender is to conclude agreements with pharmaceutical undertakings within the meaning of Paragraph 130a(8) of the Sozialgesetzbuch (SGB) Fifth Book (V) ('discount contracts or discount contract') with a term of 24 calendar months on prescription-only medicinal products and medicinal products subject to pharmacy requirements which are not subject to prescription. According to § 130a (8) sentence 1 SGB V, the invitation to tender is only addressed to pharmaceutical companies or bidding groups of pharmaceutical companies within the meaning of § 4 (18) of the German Medicines Act (AMG). It is already clarified that framework agreements with three bidders may be concluded for lots 001 to 071, framework contracts with two bidders for lots 072 to 087 and framework contracts with one bidder for lots 088 to 142.
A group of bidders is regarded as one bidder.
Further details can be found in the tender documents.
Active ingredient: acetylcysteine, prescription type: prescription, dosage form: BTA, GRA in bag, liquid application, PUL in bag liquid application, TRT, ATC code: R05CB01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Aprepitant, Prescription type: Prescription, Pharmaceutical form: HKP, ATC code: A04AD12For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Ciclopirox, Prescription type: Prescription, Dosage form: CRE, ATC code: D01AE14For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Cilostazol, Prescription type: Prescription, Dosage form: TAB, ATC code: B01AC23For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: clonidine, Prescription type: prescription, Dosage form: KAP, TAB, UTA, ATC code: C02AC01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active ingredient: Colecalciferol, Prescription type: Prescription, Dosage form: TEI, ATC code: A11CC05For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active ingredient: Desmopressin, Prescription type: Prescription, Dosage form: TAB, ATC code: H01BA02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: dexamethasone and gentamicin, Prescription type: prescription, Dosage form: ATR, ATC code: S01CA01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: dexamethasone and gentamicin, Prescription type: Prescription, Dosage form: AUS, ATC code: S01CA01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: dexamethasone and gentamicin, Prescription type: prescription, Dosage form: KPG, ATC code: S01CA01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: diazepam, prescription type: prescription, dosage form: TAB, ATC code: N05BA01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Dienogest, Prescription type: Prescription, Dosage form: FTA, TAB, ATC code: G03DB08For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Wirkstoff: Atorvastatin, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: C10AA05For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Diltiazem, Verschreibungsart: verschreibungspflichtig, Darreichungsform: REK, RET, Retard-FTA, ATC-Code: C08DB01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: dorzolamide and timolol, Prescription type: Prescription: Pharmaceutical form: EDP, ATC code: S01ED51For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active ingredient: iron II ion, prescription type: pharmacy required, dosage form: FTA, HKM, HKP, UTA, WKA, ATC code: B03AA07For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: fosaprepiant, prescription type: prescription, pharmaceutical form: PIF, ATC code: A04AD12For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: ipratropium bromide, Prescription type: prescription, Dosage form: DOS, ATC code: R03BB01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: ipratropium bromide, Prescription type: Prescription, Dosage form: LOV, ATC code: R03BB01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Mebeverin, Prescription type: Prescription, Dosage form: FTA, UTA, ATC code: A03AA04For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: meloxicam, Prescription type: Prescription, Dosage form: TAB, ATC code: M01AC06For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: methotrexate, Prescription type: Prescription, Dosage form: TAB, ATC code: L04AX03For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: methotrexate, Prescription type: Prescription: Prescription, Dosage form: PEN, ATC code: L04AX03For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Wirkstoff: Bosentan, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: C02KX01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: methylphenidate, Prescription type: prescription, Dosage form: HVW, ATC code: N06BA04For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: moclobemide, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: N06AG02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Modafinil, Prescription type: Prescription, Dosage form: TAB, ATC code: N06BA07For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Mycophenolic acid, Prescription type: Prescription, Dosage form: TMR, ATC code: L04AA06For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Nitrofurantoin, Prescription type: Prescription, Dosage form: KAP, TAB, UTA, ATC code: J01XE01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: paracetamol and codeine, prescription type: prescription, pharmaceutical form: HKP, TAB, ATC code: N02AJ06For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Piracetam, Prescription type: Prescription, Dosage form: FTA, KAP, TAB, ATC code: N06BX03For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: prednisone, Prescription type: Prescription, Dosage form: TAB, ATC code: H02AB07For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: promethazine, Prescription type: Prescription, Dosage form: FTA, TAB, UTA, ATC code: R06AD02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Prucalopride, Prescription type: Prescription, Dosage form: FTA, ATC code: A06AX05For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: bupropion, prescription type: prescription, pharmaceutical form: TAB, ATC code: N06AX12For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: pyridostigmine bromide, prescription type: prescription, dosage form: RET, ATC code: N07AA02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: pyridostigmine bromide, prescription type: prescription, dosage form: TAB, UTA, ATC code: N07AA02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: ramipril and piretanide, Prescription type: prescription: pharmaceutical form: TAB, ATC code: C09BA05For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Wirkstoff: Sotalol, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, TAB, ATC-Code: C07AA07For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: sulpiride, Prescription type: prescription, Dosage form: FTA, KAP, TAB, ATC code: N05AL01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: sultamicillin, Prescription type: Prescription, Dosage form: FTA, ATC code: J01CR04For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Terazosin, Prescription type: Prescription, Dosage form: TAB, ATC code: G04CA03For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: thiamazole, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: H03BB02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Tiaprid, Prescription type: Prescription, Dosage form: FTA, TAB, ATC code: N05AL03For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: tizanidine, Prescription type: prescription, Dosage form: TAB, ATC code: M03BX02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Calcitriol, Prescription type: Prescription, Dosage form: WKA, ATC code: A11CC04For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: triamterene and HCT, Prescription type: prescription: prescription, Dosage form: FTA, KAP, TAB, ATC code: C03EA01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Urapidil, Prescription type: Prescription, Pharmaceutical form: REK, ATC code: C02CA06For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Vancomycin standard, Prescription type: Prescription, Dosage form: HKP, ATC code: A07AA09For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Cefpodoxime, Prescription type: Prescription, Dosage form: FTA, ATC code: J01DD13For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: clozapine, Prescription type: prescription, Dosage form: TAB, ATC code: N05AH02For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Dasatinib, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: L01EA02For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Desloratadin, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, SMT, TAB, ATC-Code: R06AX27For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: dorzolamide and timolol, Prescription type: prescription, Dosage form: ATR, ATC code: S01ED51For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Acyclovir, Prescription type: Prescription, Dosage form: FTA, TAB, ATC code: J05AB01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Dutasteride and tamsulosin, Prescription type: Prescription: Dosage form: HKP, ATC code: G04CA52For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: efavirenz, emtricitabine and tenofovir disoproxil, prescription type: prescription, pharmaceutical form: FTA, ATC code: J05AR06For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: emtricitabine and tenofovir disoproxil, prescription type: prescription, dosage form: FTA, ATC code: J05AR03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Eplerenone, Prescription type: Prescription, Dosage form: FTA, ATC code: C03DA04For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Escitalopram, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, SMT, ATC-Code: N06AB10For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Eslicarbazepine, Prescription type: Prescription, Dosage form: TAB, ATC code: N03AF04For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Etoricoxib, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: M01AH05For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Exemestane, Prescription type: Prescription, Dosage form: FTA, UTA, ATC code: L02BG06For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: felodipine, Prescription type: Prescription, Dosage form: RET, ATC code: C08CA02For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Fentanyl, Prescription type: Prescription, Dosage form: TAB, ATC code: N02AB03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Agomelatine, Prescription type: Prescription, Dosage form: FTA, ATC code: N06AX22For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: fluconazole, Prescription type: prescription, Pharmaceutical form: HKP, ATC code: J02AC01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: fluoxetine, Prescription type: prescription, Dosage form: FTA, HKP, TAB, TSE, ATC code: N06AB03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active ingredient: folic acid, Prescription type: pharmacy required, Dosage form: KAP, TAB, ATC code: B03BB01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: hydromorphone, Prescription type: prescription, Dosage form: HKP, ATC code: N02AA03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: hydroxycarbamide, Prescription type: Prescription, Dosage form: HKP, ATC code: L01XX05For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Imatinib, Prescription type: Prescription, Dosage form: FTA, HKP, ATC code: L01EA01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Irbesartan, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, TAB, ATC-Code: C09CA04For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Itraconazole, Prescription type: Prescription, Dosage form: HKP, ATC code: J02AC02For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Ivabradine, Prescription type: Prescription, Dosage form: FTA, ATC code: C01EB17For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active ingredient: Lactulose, Prescription type: pharmacy required, Dosage form: SIR, ATC code: A06AD11For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active ingredient: Alfacalcidol, Prescription type: Prescription, Dosage form: WKA, ATC code: A11CC03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Latanoprost, Prescription type: Prescription, Dosage form: ATR, ATC code: S01EE01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Lenalidomide, Prescription type: Prescription, Dosage form: HKP, ATC code: L04AX04For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: levodopa, carbidopa and entacapone, prescription type: prescription, dosage form: FTA, ATC code: N04BA03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Levofloxacin, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: J01MA12For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Loperamide, Prescription type: Prescription, Dosage form: BTA, FTA, HKP, KTA, Oral lyphilisate, SMT, TAB, WKA, ATC code: A07DA03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: methocarbamol, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: M03BA03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: methotrexate, Prescription type: Prescription, Dosage form: IFE, ATC code: L04AX03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: metronidazole, Prescription type: Prescription, Dosage form: FTA, KAP, TAB, UTA, ATC code: P01AB01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active ingredient: Mometasone furoat, Prescription type: Prescription, Dosage form: NAS, SUS, ATC code: R01AD09For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Olanzapine, Prescription type: Prescription, Dosage form: FTA, SMT, TAB, UTA, ATC code: N05AH03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: amisulpride, Prescription type: Prescription, Dosage form: FTA, TAB, ATC code: N05AL05For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: olmesartan and amlodipine, prescription type: prescription, pharmaceutical form: FTA, ATC code: C09DB02For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: oxycodone and naloxone, Prescription type: prescription, Dosage form: RET, ATC code: N02AA55For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Palonosetron, Prescription type: Prescription, Dosage form: ILO, ATC code: A04AA05For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: paracetamol and tramadol, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: N02AJ13For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Paroxetine, Prescription type: Prescription, Dosage form: FTA, TAB, ATC code: N06AB05For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: posaconazole, prescription type: prescription, pharmaceutical form: TMR, ATC code: J02AC04For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Prasugrel, Prescription type: Prescription, Dosage form: FTA, ATC code: B01AC22For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Pregabalin, Prescription type: Prescription, Dosage form: HKP, TAB, ATC code: N03AX16For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: riluzole, Prescription type: prescription, Pharmaceutical form: FTA, ATC code: N07XX02For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Rivastigmine, Prescription type: Prescription, Dosage form: HKP, ATC code: N06DA03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: amlodipine and valsartan, prescription type: prescription, pharmaceutical form: FTA, ATC code: C09DB01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Rivastigmine, Prescription type: Prescription, Dosage form: PFT, ATC code: N06DA03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: silodosin, Prescription type: prescription, Dosage form: ICP, ATC code: G04CA04For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: solifenacin, Prescription type: Prescription, Dosage form: FTA, ATC code: G04BD08For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Sorafenib, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: L01EX02For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Sumatriptan, Prescription type: Prescription, Dosage form: FTA, TAB, UTA, ATC code: N02CC01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: sunitinib, Prescription type: Prescription, Dosage form: HKP, ATC code: L01EX01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Tadalafil, Prescription type: Prescription, Dosage form: FTA, ATC code: G04BE08For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Tamoxifen, Prescription type: Prescription, Dosage form: FTA, TAB, ATC code: L02BA01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Wirkstoff: Tenofovir disoproxil, Verschreibungsart: verschreibungspflichtig, Darreichungsform: FTA, ATC-Code: J05AF07For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Travoprost and timolol, Prescription type: Prescription: Dosage form: ATR, ATC code: S01ED51For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: amlodipine, olmesartan and HCT, prescription type: prescription, dosage form: FTA, ATC code: C09DX03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: valganciclovir, prescription type: prescription, dosage form: FTA, ATC code: J05AB14For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Voriconazole, Prescription type: Prescription, Dosage form: FTA, ATC code: J02AC03For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active ingredient: Baclofen, Prescription type: prescription, Dosage form: TAB, ATC code: M03BX01For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: beclometasone dipropionate, prescription type: prescription, dosage form: DOS, ATC code: R03BA01For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Colecalciferol, Prescription type: Prescription, Dosage form: WKA, ATC code: A11CC05For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Enoxaparin sodium 2,000 IU, Prescription type: Prescription, Dosage form: ILO, ATC code: B01AB05For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Enoxaparin sodium 4,000 IU, Prescription type: Prescription, Dosage form: ILO, ATC code: B01AB05For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Enoxaparin sodium 6,000 IU, Prescription type: Prescription, Dosage form: ILO, ATC code: B01AB05For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Enoxaparin sodium 8,000 IU, Prescription type: Prescription, Dosage form: ILO, ATC code: B01AB05For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Enoxaparin sodium 10,000 IU, Prescription type: Prescription: Prescription, Dosage form: ILO, ATC code: B01AB05For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: amlodipine, valsartan and HCT, prescription type: prescription, pharmaceutical form: FTA, ATC code: C09DX01For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: fexofenadine, prescription type: prescription, dosage form: FTA, ATC code: R06AX26For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active ingredient:Fosfomycin, Prescription type: Prescription, Dosage form: GRA for oral solution, Powder for oral solution, ATC code: J01XX01For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Indapamide, Prescription type: Prescription, Dosage form: RET, ATC code: C03BA11For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: indapamide, prescription type: prescription, pharmaceutical form: FTA, ICP, ATC code: C03BA11For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: ramipril and amlodipine, Prescription type: prescription, Dosage form: HKP, ATC code: C09BB07For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: sulfasalazine, Prescription type: Prescription, Dosage form: FMR, TAB, TMR, ATC code: A07EC01For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: Travoprost, Prescription type: Prescription, Dosage form: ATR, ATC code: S01EE04For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: ursodeoxycholic acid, prescription type: prescription, pharmaceutical form: FTA, ICP, TAB, ATC code: A05AA02For lots 072 to 087, framework contracts are concluded with 2 economic operators.
If, in the case of the lots in the 2-partner model, the difference in savings between the potentially first and second placed offers of a lot is greater than 40%, then the respective second-placed offer with regard to this lot falls out of the evaluation and the award is ultimately made in the 1-partner model.
Active substance: abacavir and lamivudine, Prescription type: prescription, Pharmaceutical form: FTA, ATC code: J05AR02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Acitretin, Prescription type: Prescription, Dosage form: HKP, ATC code: D05BB02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: anagrelide, Prescription type: prescription, Pharmaceutical form: HKP, ATC code: L01XX35For lots 001 to 071, framework contracts are concluded with 3 economic operators. If, in the case of the lots in the 3-partner model, the difference in savings between the potential first and second placed offers of a lot to be awarded is greater than 40%, then the respective second- and third-placed bids regarding this lot fall out of the evaluation and the award is ultimately made in the 1-partner model.
If the difference in savings between the second and third placed offers of a lot for the lots in the 3-partner model is greater than 40%, the respective third-placed offer with respect to that lot falls out of the classification and the bid is ultimately awarded in the 2-partner model.
Active substance: Alprazolam, Prescription type: Prescription, Dosage form: TAB, ATC code: N05BA12For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: amantadine, Prescription type: prescription, Dosage form: FTA, ATC code: N04BB01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Atenolol and chlortalidone, Prescription type: Prescription, Dosage form: FTA, ATC code: C07CB03For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Benazepril and HCT, Prescription type: Prescription: Prescription, Dosage form: FTA, ATC code: C09BA07For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Wirkstoff: Bezafibrat, Verschreibungsart: verschreibungspflichtig, Darreichungsform: RET, RED, Retard-FTA, ATC-Code: C10AB02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Bimatoprost, Prescription type: Prescription, Dosage form: ATR (including EDP), ATC code: S01EE03For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: budesonide, prescription type: prescription, dosage form: SUV, ATC code: R03BA02For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: Cabergoline, Prescription type: Prescription, Dosage form: TAB, ATC code: N04BC06For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: carbamazepine, Prescription type: prescription, Dosage form: TAB, ATC code: N03AF01For lots 088 to 142, framework contracts shall be concluded with an economic operator.
Active substance: carbimazole, Prescription type: prescription, Dosage form: FTA, TAB, ATC code: H03BB01For lots 088 to 142, framework contracts shall be concluded with an economic operator.